Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Absolute Bioavailability of Vemurafenib in Patients With BRAF(V600) Mutation-Positive Malignancies.
Zhang W, Colburn D, Simmons B, Papai Z, Bertran E, Schadt S, Husser C, Forbes H, Roethlisberger D, Hartung T. Zhang W, et al. Clin Pharmacol Drug Dev. 2020 May;9(4):496-504. doi: 10.1002/cpdd.773. Epub 2020 Feb 21. Clin Pharmacol Drug Dev. 2020. PMID: 32083398 Clinical Trial.
Patients received oral vemurafenib 960 mg twice daily on days 1 through 28, with a single intravenous infusion of (14) C-labeled vemurafenib solution (3 mL, corresponding to a radioactive dose of 18.5 kBq and a vemurafenib dose of 20 g) g …
Patients received oral vemurafenib 960 mg twice daily on days 1 through 28, with a single intravenous infusion of (14) C …
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma.
Goldinger SM, Rinderknecht J, Dummer R, Kuhn FP, Yang KH, Lee L, Ayala RC, Racha J, Geng W, Moore D, Liu M, Joe AK, Bazan SP, Grippo JF. Goldinger SM, et al. Pharmacol Res Perspect. 2015 Mar;3(2):e00113. doi: 10.1002/prp2.113. Pharmacol Res Perspect. 2015. PMID: 25729580 Free PMC article.
This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vemurafenib in patients with metastatic melanoma. Seven patients with metastatic BRAF-mutated melanoma received unlabeled vemurafenib …
This study characterized mass balance, metabolism, rates/routes of elimination, and disposition of (14)C-labeled vem …